

8 February 2017

ASX ANNOUNCEMENT

Penthrox launched in France and Belgium and first sales.

Medical Developments International Limited (ASX: MVP) is delighted to announce Penthrox has been launched in both France and Belgium via its European partner, the Mundipharma network of independent associated companies (Mundipharma).

The “First Commercial Sale” in France triggers a milestone payment of USD\$2.0m to MVP which will be received within 30 days.

MVP CEO, Mr John Sharman, said: “The launch of Penthrox in France is an exciting achievement for MVP. France represents a significant market for Penthrox within Europe and pre-launch feedback from the market is extremely positive.”

Enquiries:

David Williams
Chairman
Medical Developments International Ltd
+61 414 383 593

John Sharman
Chief Executive Officer
Medical Developments International Ltd
+61 3 9547 1888

**About Pentrox**

Penthrox is a fast onset, non-opioid analgesic which is indicated in Australia for pain relief by self-administration in patients with trauma and those requiring analgesia for surgical procedures. Penthrox has been used safely and effectively for more than 30 years in Australia with excess of 5 million units sold. Mundipharma International has exclusive product rights in 39 European markets (including France, Germany, Italy and Spain, but excluding Hungary, Republic of Ireland and the United Kingdom).

About Medical Developments International Ltd

MVP is an Australian company delivering emergency medical solutions dedicated to improving patient outcomes. MVP is a leader in emergency pain relief and respiratory products. The Company manufactures Penthrox®, a fast acting trauma & emergency pain relief product. It is used in Australian Hospitals including Emergency Departments, Australian Ambulance Services, the Australian Defence Forces, Sports Medicine and for analgesia during short surgical procedures such as Dental and Cosmetic surgery as well as in other medical applications. MVP is expanding internationally and manufactures a range of world-leading Asthma respiratory devices.